NYSE · Financial Statements

Bristol-Myers Squibb Company (BMY) Revenue, Earnings & Financial Statements

$63.04 NYSE: BMY Market Cap $128.86B

Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

Bristol-Myers Squibb Company most recently reported annual revenue of $48.2B, net profit of $7.1B. Revenue grew at an average annual rate of 2.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Bristol-Myers Squibb Company: Revenue rose from $19.4B in 2016 to $48.2B in 2025, a change of +148.1% over 9 years; net profit was positive in 8 of 10 reported years; operating margin moved from 23.0% to 28.5%, a shift of +5.5 percentage points; the most recent year shows net profit of $7.1B.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$19.4B$20.8B$22.6B$26.1B$42.5B$46.4B$46.2B$45.0B$48.3B$48.2B
Operating Expenses$15.0B$17.3B$17.4B$20.2B$40.3B$37.8B$37.1B$36.8B$42.4B$34.5B
Operating Profit$4.5B$3.4B$5.1B$5.9B$2.2B$8.5B$9.1B$8.2B$5.9B$13.7B
Operating Margin23.0%16.6%22.7%22.6%5.1%18.4%19.7%18.2%12.2%28.5%
Other Income$1.4B$1.7B$854.0M−$938.0M−$9.0B−$439.0M−$1.4B$245.0M−$14.3B−$4.4B
Interest$167.0M$196.0M$183.0M$656.0M$1.4B$1.3B$1.2B$1.2B$1.9B$1.9B
Depreciation$382.0M$789.0M$637.0M$1.7B$10.4B$10.7B$10.3B$9.8B$9.6B$4.0B
Profit Before Tax$5.9B$5.1B$6.0B$5.0B−$6.9B$8.1B$7.7B$8.4B−$8.4B$9.3B
Tax rate (%)23.8%81.0%17.1%30.4%-30.9%13.4%17.7%4.7%-6.6%24.4%
Net Profit$4.5B$1.0B$4.9B$3.4B−$9.0B$7.0B$6.3B$8.0B−$8.9B$7.1B
EPS$2.65$0.61$3.03$2.01−$3.98$3.12$2.95$3.86−$4.41$3.45

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$11.0B$11.5B$11.9B$12.2B$11.9B$12.3B$11.2B$12.3B$12.2B$12.5B$11.5B$13.0B
Operating Expenses$8.9B$9.5B$10.3B$9.6B$9.6B$9.8B$7.7B$8.5B$8.6B$9.7B$8.1B$8.9B
Operating Profit$2.1B$2.0B$1.5B$2.6B$2.3B$2.5B$3.5B$3.8B$3.6B$2.8B$3.4B$4.1B
Operating Margin19.2%17.0%12.9%21.2%19.2%20.5%31.2%30.8%29.8%22.5%29.3%31.5%
Interest$280.0M$316.0M$425.0M$521.0M$505.0M$496.0M$494.0M$485.0M$480.0M$432.0M$411.0M$407.0M
Profit Before Tax$2.1B$1.7B−$11.5B$1.3B$1.7B$175.0M$3.0B$1.8B$3.1B$1.5B$3.2B$4.1B
Tax rate (%)9.5%-5.3%-3.4%-30.9%27.5%56.6%17.1%25.9%29.5%26.1%17.3%18.8%
Net Profit$1.9B$1.8B−$11.9B$1.7B$1.2B$72.0M$2.5B$1.3B$2.2B$1.1B$2.7B$3.3B
EPS$0.93$0.87−$5.89$0.83$0.60$0.04$1.20$0.64$1.08$0.53$1.31$1.62

Over the 10 years reported for Bristol-Myers Squibb Company, borrowings increased from $6.7B in 2016 to $47.1B in 2025, cash stood at $10.2B in the latest year, shareholders' equity was $292.0M, current assets covered current liabilities 1.26 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$33.7B$33.6B$35.0B$129.9B$118.5B$109.3B$96.8B$95.2B$92.6B$90.0B
Current Assets$13.7B$14.9B$17.7B$29.4B$30.2B$33.3B$27.3B$31.8B$29.8B$29.4B
Cash$4.2B$5.4B$6.9B$12.3B$14.5B$14.0B$9.1B$11.5B$10.3B$10.2B
Inventory$1.2B$1.2B$1.2B$4.3B$2.1B$2.1B$2.3B$2.7B$2.6B$2.7B
Receivables$5.5B$6.3B$5.7B$7.7B$10.6B$12.5B$13.9B$15.3B$14.4B$14.5B
Fixed Assets$5.0B$5.0B$5.0B$7.0B$6.7B$7.0B$7.5B$8.0B$8.4B$9.1B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$4.8B$3.9B$3.6B$7.2B$6.4B$6.0B$2.3B$3.3B$3.0B$3.0B
Other Assets$6.9B$6.9B$6.5B$22.5B$20.5B$20.5B$21.1B$21.2B$21.7B$21.8B
Total Liabilities$17.4B$21.7B$20.9B$78.2B$80.6B$73.3B$65.7B$65.7B$76.2B$71.5B
Current Liabilities$8.8B$9.6B$10.7B$18.3B$19.1B$21.9B$21.9B$22.3B$23.8B$23.4B
Borrowings$6.7B$8.0B$7.3B$47.5B$51.7B$45.6B$40.7B$41.5B$51.2B$47.1B
Other Liabilities$10.7B$13.7B$13.5B$30.7B$28.9B$27.7B$25.0B$24.2B$25.0B$24.4B
Equity$221.0M$221.0M$221.0M$292.0M$292.0M$292.0M$292.0M$292.0M$292.0M$292.0M
Reserves$16.2B$11.7B$14.0B$51.6B$37.8B$35.9B$31.1B$29.4B$16.3B$18.5B

For Bristol-Myers Squibb Company, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $12.8B; free cash flow was positive in 10 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$3.1B$5.3B$7.1B$8.2B$14.1B$16.2B$13.1B$13.9B$15.2B$14.2B
Investing Cash Flow$265.0M−$1.1B−$3.0B−$10.7B−$11.6B−$1.5B−$2.2B−$3.5B−$22.6B−$5.4B
Financing Cash Flow−$216.0M−$2.5B−$374.0M−$7.4B−$1.0B−$5.6B−$7.0B−$5.1B$0$0
Net Cash Flow$1.9B$1.2B$1.5B$5.9B$2.2B−$657.0M−$5.0B$2.2B−$1.2B−$137.0M
Free Cash Flow$1.8B$4.2B$6.1B$7.4B$13.3B$15.2B$11.9B$12.7B$13.9B$12.8B

Valuation & Return Ratios

MetricValue
PEG Ratio4.88
EV / EBITDA9.24
FCF Yield10.11%
Quick Ratio1.14
Interest Coverage7.26
Return 1Y36.24%
Return 3Y44.62%
Return 5Y30.20%

Bristol-Myers Squibb Company (BMY) financials — frequently asked questions

What is Bristol-Myers Squibb Company's annual revenue?

Bristol-Myers Squibb Company (BMY) reported annual revenue of $48.2B in its most recent fiscal year.

What is Bristol-Myers Squibb Company's net profit?

Bristol-Myers Squibb Company (BMY) reported net profit of $7.1B in its most recent fiscal year.

What is BMY EV/EBITDA?

Bristol-Myers Squibb Company's enterprise value to EBITDA (EV/EBITDA) ratio is 9.24.

Revenue and earnings of other Drug Manufacturers - General stocks

LLY revenue $65.2BJNJ revenue $94.2BABBV revenue $61.2BMRK revenue $64.9BNVS revenue $54.8BAZN revenue $58.7BAMGN revenue $36.7BGILD revenue $29.4BNVO revenue $309.1BPFE revenue $62.6BAll Drug Manufacturers - General stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
BMY Overview BMY Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.